Skip to content

Effects of Palmar Cooling on the Human Immune System

Understanding and Mitigating Delayed Onset Muscle Soreness (DOMS)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07215338
Enrollment
22
Registered
2025-10-10
Start date
2024-06-28
Completion date
2024-09-27
Last updated
2025-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human Immune Response

Keywords

Palmar Cooling, Human Immunology, Exercise Immunology

Brief summary

This is a research study on human exercise that will investigate the immune system response post-exercise and how it relates to Delayed Onset Muscle Soreness (DOMS), and possible causes for DOMS. Blood draws (10mL) will be obtained at 5 timepoints: Baseline before intervention, day of exercise immediately following exercise, and post-exercise days 1, 2 and 4. Point of care lactate levels obtained before and after exercise. Subjective pain scores recorded daily starting immediately after after exercise.

Interventions

OTHERMuscle Temperature Control

The intervention will be placing the palms of the hands on a water perfused pad.

Sponsors

Wu Tsai Human Performance Alliance
CollaboratorUNKNOWN
Stanford University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Intervention model description

Control arm has palmar temperature device set to 30 degrees celsius, interventional arm has palmar temperature device set to 14 degrees celsius.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

\- Ability to perform two arm bicep curl of at least 35 lb as 1 repetition maximum

Exclusion criteria

* Autoimmune disease * Steroid use * On current immune-modifying treatment

Design outcomes

Primary

MeasureTime frameDescription
Mean change from baseline in phosphorylation markers in the Janus kinase/signal transducer and activator of transcription (JAK/STAT) and Toll-like Receptor (TLR)-pathway in immune cell populationsFrom enrollment to 5 days after the end of treatmentCollected at baseline from whole blood prior to exercise, day of exercise, post-exercise day 1, post-exercise day 2, post-exercise day 4

Secondary

MeasureTime frameDescription
Change from pre-exercise baseline in point of care lactate levels1 dayTwo point of care lactate draws before and after exercise obtained in mmol/L
Change in Pain Scores from baselineFrom day of intervention daily for 5 days.Daily subjective pain scores recorded according to the Borg Perceived Pain Scale from 0 (no pain) to 11 (maximum pain)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026